At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
EGb 761 120 mg +1 moredrug
Likely dose
EGb 761 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia. A 3 Month, Phase II, Randomised, Double Blind, Placebo Controlled, Parallel Group Clinical Study.
In Brief
A Phase 2 clinical trial evaluating EGb 761 120 mg and Placebo for Friedreich Ataxia. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus placebo in patients suffering from Friedreich Ataxia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFriedreich Ataxia
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJan 2009
Primary CompletionOct 2011
TodayJul 2026
First PostedJan 16, 2009
Enrollment StartJun 1, 2008
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.5 years ago
Interventions
EGb 761 120 mgdrug
EGb 761® 120 mg bid, orally for 12 to 14 weeks
Placebodrug
Placebo 1 tablet BID, orally for 12 to 14 weeks